---
layout: post
title: "Determination of Regulatory Review Period for Purposes of Patent Extension; EXKIVITY"
date: 2026-02-05 18:57:50 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-27004
original_published: 2023-12-08 00:00:00 +0000
significance: 8.00
---

# Determination of Regulatory Review Period for Purposes of Patent Extension; EXKIVITY

**Published:** February 05, 2026 18:57 UTC
**Source:** Federal Register
**Original Published:** December 08, 2023 00:00 UTC
**Document Number:** 2023-27004

## Summary

The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for EXKIVITY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claims that human drug product.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/12/08/2023-27004/determination-of-regulatory-review-period-for-purposes-of-patent-extension-exkivity)
- API: https://www.federalregister.gov/api/v1/documents/2023-27004

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
